GlassScriptPhysician profile
Albert C Leung
NPI 1487626578
$5,938.73
in general payments reported to CMS, 2019-2025
13 companies · $4,238 in 2025
The $4,238 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $93.52 · 2021: $238 · 2022: $249 · 2023: $404 · 2024: $231 · 2025: $4,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,494 · Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,493.93 |
| Food and Beverage | $1,378.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,967.35 | 2025 | |
| Astellas Pharma US INC | $486.38 | 2019-2024 | Veozah, Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $455.74 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $246.81 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $191.53 | 2019-2021 | |
| Boston Scientific Corporation | $132.24 | 2023-2024 | Rezum Generator |
| Ferring Pharmaceuticals INC. | $108.84 | 2019 | |
| Pfizer INC. | $101.57 | 2019-2023 | |
| Myovant Sciences INC. | $81.27 | 2021-2022 | |
| Urovant Sciences INC | $78.10 | 2021-2022 | |
| Abbvie INC. | $39.09 | 2023-2024 | |
| Myriad Genetic Laboratories, INC. | $36.58 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.